TY - T1的吸入型皮质类固醇激素和pneumonia mortality in COPD patients JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01035-2019 VL - 54 IS - 3 SP - 1901035 AU - Almagro, Pere AU - Martinez-Camblor, Pablo AU - Soriano, Joan B. Y1 - 2019/09/01 UR - //www.qdcxjkg.com/content/54/3/1901035.abstract N2 - In a recent article, Suissa [1] proposes several alternative hypotheses to explain the paradoxical effect of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) patients, whereby these drugs can increase the risk of pneumonia and simultaneously reduce pneumonia mortality. In our opinion, the conclusion of the article, that pneumonia mortality is increased in COPD patients treated with ICS, both in observational and in randomised clinical trials (RCTs), is not supported by data and cannot be considered confirmed. Basically, the author maintains that this paradox can be explained by the small number of events in randomised clinical trials (RCTs) and selection bias in observational studies [1].Chronic use of ICS increases the risk of pneumonia in COPD patients, although this risk is not homogenous. This study confirms that the risk of pneumonia-related mortality in randomised clinical trials is not increased in patients treated with ICS. http://bit.ly/2Zod6us ER -